Publicação: In vivo study of novel nanocomposite for prostate cancer treatment
Carregando...
Arquivos
Data
2015-05-26
Orientador
Coorientador
Pós-graduação
Curso de graduação
Título da Revista
ISSN da Revista
Título de Volume
Editor
Tipo
Trabalho apresentado em evento
Direito de acesso
Acesso aberto
Resumo
Because of high occurrence of side effects of conventional anticancer drugs, new therapies have been widely studied, such as the use of non-usual molecules and the association with nanomaterials. In this context, sildenafil is a molecule that has been lately considered as a co-adjuvant in cancer therapy because it inhibits an enzyme with a potential role in tumor progression, phosphodiesterase-5. Taking into account the combination of nanoparticles and sildenafil, we produced systems based on mesoporoussilica nanoparticles, Pluronic F-127 and sildenafil as the main therapy for prostate cancer.
Descrição
Palavras-chave
Idioma
Inglês
Como citar
Journal of Physics: Conference Series, v. 617, n. 1, 2015.
